Annuncio • Jul 14
Agilent Technologies Receives Fda Approval for Pd-L1 Ihc 28-8 Pharmdx in Esophageal Squamous Cell Carcinoma, Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma Agilent Technologies Inc. has received U.S. Food and Drug Administration (FDA) approval for the PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase-nvhy), Bristol Myers Squibb’s PD-1-targeted immunotherapeutic agents. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. PD-L1 IHC 28-8 pharmDx, Code SK005, is an FDA-approved diagnostic aid for detecting PD-L1 expression (Combined Positive Score [CPS] = 1) in these tumor types for patients being considered for treatment with OPDIVO® or OPDIVO QVANTIG®. PD-L1 expression is determined using CPS, which measures PD-L1 staining in tumor and immune cells relative to the total number of viable tumor cells. Gastric and esophageal cancers continue to represent a significant global health burden, with high mortality rates and limited long-term survival for many patients. Esophageal cancer is the 11th most common cancer worldwide with over 510,000 new cases and is the seventh leading cause of cancer mortality, accounting for over 445,000 cancer deaths each year. Patients with esophageal cancer have an overall five-year survival of 22%. Gastric cancer is the fifth most common cancer worldwide with around 968,000 new cases and is also the fifth leading cause of cancer mortality, accounting for approximately 660,000 cancer deaths each year. Patients with gastric cancer have an overall 5-year survival of 38%. PD-1- and PD-L1-targeted immunotherapies, including OPDIVO®, have transformed treatment approaches across multiple cancer types, underscoring the importance of accurate biomarker testing to help identify patients who may benefit from these therapies. PD-L1 IHC 28-8 pharmDx was developed by Agilent in partnership with Bristol Myers Squibb as part of the clinical development program supporting OPDIVO®. Clinical studies CheckMate-648 and CheckMate-649 demonstrated improvements in overall survival and progression-free survival in patients with ESCC, gastric, GEJ, and esophageal adenocarcinoma treated with OPDIVO® and OPDIVO QVANTIG®. PD-L1 IHC 28-8 pharmDx is manufactured by Agilent Technologies, Inc. Annuncio • Jul 08
Agilent Technologies Inc. Expands Altura Portfolio with Inert Size Exclusion and Plrp-S Columns for Biotherapeutic Analysis Agilent Technologies Inc. announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production. The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody ratio determination is critical for characterizing antibody-drug conjugates and other conjugated therapeutics as drug modalities continue to increase in complexity. By extending the Altura HPLC columns with Ultra Inert technology to SEC and PLRP-S columns, Agilent Technologies Inc. is expanding access to inert separation technologies that help scientists achieve more reliable, accurate and reproducible results across critical biopharma analytical workflows. Aggregate analysis is a critical quality attribute for a wide range of biotherapeutics, including monoclonal antibodies, antibody-drug conjugates, and emerging modalities. Altura SEC columns build on the success of the Agilent AdvanceBio SEC columns while incorporating Ultra Inert technology to enhance peak shape and aggregate recovery. For aggregate analysis of GLP-1 peptides, Altura SEC columns deliver up to double the sensitivity of inert competitor columns, improving detection of low-level impurities. For liquid chromatography/mass spectrometry (LC/MS) workflows, Altura PLRP-S columns are designed to deliver robust performance under demanding conditions. These capabilities support molecular weight confirmation across protein-based therapeutics and complex biopharmaceutical modalities. The new columns are engineered to deliver faster conditioning, improved peak shape and enhanced sensitivity for challenging analytes. These performance improvements support a broad range of therapeutic modalities, from peptide therapeutics such as GLP-1 to oligonucleotides and large biomolecules including monoclonal antibodies and mRNA. As analytical demands continue to evolve, laboratories require robust and reproducible solutions to support development and quality workflows. Altura columns are part of Agilent's broader portfolio of inert liquid chromatography solutions, designed to provide a fully optimized sample flow path when used in conjunction with Agilent instrumentation and supplies. This integrated approach helps laboratories improve workflow efficiency while maintaining data quality and consistency. The Altura SEC and Altura PLRP-S columns are available globally. Annuncio • Jul 01
Agilent Technologies Launches Xcelligence RTCA Esight AI Module Agilent Technologies Inc. announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach is expected to provide biopharma researchers with a more complete view of cell behavior while reducing variability across users and conditions. Traditional cell segmentation workflows rely on time-consuming and subjective manual setup and analysis steps that increase variability, error and rework, slowing experimental timelines while also requiring a higher level of experimental expertise to achieve consistent results. As biopharma research increasingly demands more complex experiments, higher throughput and greater consistency, integrated workflows are key to efficient scientific progress. AI-driven imaging analysis can help reduce variability across users while decreasing time spent on manual analysis. By replacing subjective, user-influenced thresholding and manual parameter tuning with a one-click approach, the new module delivers standardized analysis across skill levels, experiments and datasets. eSight imaging AI analysis is designed to ensure confident, reliable performance across users, cell types and assay conditions, providing the robustness and accuracy essential for real-world science and users with varying levels of imaging expertise. The new module is expected to reduce time spent on manual analysis, rework and training while supporting broader application of label-free imaging workflows, specifically within drug discovery and in high-throughput biopharma research. By simplifying label-free imaging analysis within an integrated imaging and impedance workflow, eSight AI helps researchers reduce complexity, gain more confident biological insights and accelerate the path from experiment to interpretation. Annuncio • Jun 26
Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP. Agilent Technologies, Inc. (NYSE:A) entered into a definitive agreement to acquire Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP for approximately $950 million on March 9, 2026. A cash consideration of $950 million will be paid by Agilent Technologies, Inc. As part of consideration, $950 million is paid towards common equity of Biocare Medical, LLC. Upon close, Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group.
For the period ending December 31, 2025, Biocare Medical, LLC reported total revenue of $90 million.
The transaction is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close by no later than Agilent's fourth fiscal quarter of 2026. The deal is expected to be accretive to Agilent’s top-line growth rate, margin profile and non-instrument revenue mix in the first year. The transaction is expected to become accretive to Agilent’s EPS approximately 12 months following close.
Barclays Capital Inc. acted as financial advisor for Agilent Technologies, Inc. Sullivan & Cromwell LLP acted as legal advisor for Agilent Technologies, Inc. Joele Frank is serving as strategic communications adviser to Agilent. Jefferies LLC acted as financial advisor for Biocare Medical, LLC. Ropes & Gray LLP acted as legal advisor for Biocare Medical, LLC. Barclays Bank PLC acted as financial advisor for Agilent Technologies, Inc. ICR Healthcare is serving as strategic communications adviser to Biocare.
Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP on June 25, 2026. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group. Upcoming Dividend • Jun 23
Upcoming dividend of US$0.26 per share Eligible shareholders must have bought the stock before 30 June 2026. Payment date: 22 July 2026. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (0.9%). Recent Insider Transactions • Jun 06
Independent Director recently sold €186k worth of stock On the 29th of May, G. Dolsten sold around 2k shares on-market at roughly €116 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €922k more than they bought in the last 12 months. 
